Halozyme Therapeutics Inc.

-1.11 (-2.76%)
Products, Regulatory

Halozyme Announces CHMP Recommends EU Approval Of Roche's Phesgo For Her2-Positive Breast Cancer

Published: 11/13/2020 18:50 GMT
Halozyme Therapeutics Inc (HALO) - Halozyme Announces Chmp Recommends Eu Approval of Roche's Phesgo® (fixed-dose Combination of Perjeta® and Herceptin® for Subcutaneous Injection) Utilizing Halozyme's Enhanze® Technology for Her2-positive Breast Cancer.
Halozyme Therapeutics- Based on Chmp Recommendation, a Final Decision Regarding Approval of Phesgo is Expected From European Commission in Near Future.
Halozyme Therapeutics Inc - Recommendation From Chmp is Based on Results From Pivotal Phase Iii Federica Study, Which Met Its Primary Endpoint.
Halozyme Therapeutics Inc - U.S. FDA Recently Expedited Approval of Phesgo for Treatment of Early and Metastatic Her2-positive Breast Cancer.